Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Abbott's Strategic Acquisition of Exact Sciences to Boost Cancer Diagnostics Market Leadership Abbott is set to finalize its acquisition of Exact Sciences on March 23, 2026, reinforcing its position in the cancer diagnostics sector.

Abbott's Strategic Acquisition of Exact Sciences to Boost Cancer Diagnostics Market Leadership #United_States #Abbott #Cancer_Diagnostics #Abbott_Park,_Illinois #Exact_Sciences

Thiard News@F4F

@newsen.bsky.social

2 months ago

Lunit's Commitment to AI in Healthcare at the 2026 World Economic Forum Lunit, a leader in AI for cancer diagnostics, will take part in the 2026 World Economic Forum as an Associate Partner to discuss AI's role in improving healthcare.

Lunit's Commitment to AI in Healthcare at the 2026 World Economic Forum #AI #South_Korea #Seoul #Lunit #Cancer_Diagnostics

Thiard News@F4F

@newsen.bsky.social

3 months ago

Wobble Genomics Reveals Advances in HER2 Profiling at SABCS 2025 Wobble Genomics showcases its innovative platform for detailed HER2 profiling in breast cancer at SABCS 2025, offering new precision in diagnostics.

Wobble Genomics Reveals Advances in HER2 Profiling at SABCS 2025 #United_Kingdom #Edinburgh #Cancer_Diagnostics #Wobble_Genomics #HER2_profiling

Thiard News@F4F

@newsen.bsky.social

4 months ago

Abbott's Acquisition of Exact Sciences Sets New Standard in Cancer Care Innovations Abbott's recent acquisition of Exact Sciences aims to revolutionize cancer diagnostics and enhance early detection, benefiting millions.

Abbott's Acquisition of Exact Sciences Sets New Standard in Cancer Care Innovations #USA #Abbott #Cancer_Diagnostics #Abbott_Park,_Illinois #Exact_Sciences

Thiard News@F4F

@newsen.bsky.social

5 months ago

Cha-Mei Tang Recognized as Pinnacle Professional Member for Cancer Diagnostic Innovations Dr. Cha-Mei Tang, a leader in cancer diagnostics, has been honored as a Pinnacle Professional Member for her groundbreaking work on cancer screening blood tests.

Cha-Mei Tang Recognized as Pinnacle Professional Member for Cancer Diagnostic Innovations #United_States #Cancer_Diagnostics #Potomac #Creatv_MicroTech #Cha-Mei_Tang

Thiard News@F4F

@newsen.bsky.social

5 months ago

Molecular Cytogenetics Market Growth Projected to Reach $1.43 Billion by 2030 The global Molecular Cytogenetics Market is set to grow significantly, reaching $1.43 billion by 2030, driven by rising cancer cases and technological advancements.

Molecular Cytogenetics Market Growth Projected to Reach $1.43 Billion by 2030 #USA #Delray_Beach #Cancer_Diagnostics #Genetic_Disorders #Molecular_Cytogenetics

Thiard News@F4F

@newsen.bsky.social

6 months ago

Immunohistochemistry Market to Reach $5.14 Billion by 2030 Driven by Clinical Demands and Innovations The global Immunohistochemistry Market is set to reach $5.14 billion by 2030, fueled by rising cancer incidents and technological innovations in diagnostics.

Immunohistochemistry Market to Reach $5.14 Billion by 2030 Driven by Clinical Demands and Innovations #Market_Growth #Cancer_Diagnostics #Immunohistochemistry

Thiard News@F4F

@newsen.bsky.social

6 months ago

Liquid Biopsy Market Growth Fueled by Rising Cancer Rates and Non-Invasive Tests The liquid biopsy market is projected to reach USD 30.65 billion by 2035, with a CAGR of 9.41%, driven by increasing cancer prevalence and demand for non-invasive diagnostics.

Liquid Biopsy Market Growth Fueled by Rising Cancer Rates and Non-Invasive Tests #None #Liquid_Biopsy #Cancer_Diagnostics #Non-Invasive_Testing

Thiard News@F4F

@newsen.bsky.social

7 months ago

Cancer Diagnostics Market Set to Reach USD 215 Billion by 2035: Insights from Vantage Market Research The global cancer diagnostics market is poised for significant growth, expected to reach USD 215 billion by 2035, driven by rising cancer rates and advancements in technology.

Cancer Diagnostics Market Set to Reach USD 215 Billion by 2035: Insights from Vantage Market Research #USA #New_York #Early_Detection #Cancer_Diagnostics #Vantage_Market_Research

Thiard News@F4F

@newsen.bsky.social

7 months ago

Significant Growth Forecast for Cancer Diagnostics Market by 2032 Driven by Technology and Demand The cancer diagnostics market is set for robust growth, driven by rising cancer rates and innovative technologies, projected to reach USD 48.49 billion by 2032.

Significant Growth Forecast for Cancer Diagnostics Market by 2032 Driven by Technology and Demand #USA #Massachusetts #FDA #Cancer_Diagnostics #SkyQuest

Thiard News@F4F

@newsen.bsky.social

7 months ago

The Growing Landscape of Minimal Residual Disease Testing by 2032: Insights and Innovations The demand for minimal residual disease testing is set to surge, driven by advancements in diagnostics and increasing cancer prevalence. Explore market dynamics.

The Growing Landscape of Minimal Residual Disease Testing by 2032: Insights and Innovations #United_States #Las_Vegas #Cancer_Diagnostics #Minimal_Residual_Disease #Molecular_Testing

Thiard News@F4F

@newsen.bsky.social

8 months ago

mRNA Sequencing Market Projected to Reach $4.02 Billion by 2031 Amid Rising Cancer Cases The mRNA sequencing market is set to surge, driven by increasing cancer prevalence and demand for diagnostic tools, reaching $4.02 billion by 2031.

mRNA Sequencing Market Projected to Reach $4.02 Billion by 2031 Amid Rising Cancer Cases #USA #New_York #Cancer_Diagnostics #The_Insight_Partners #mRNA_Sequencing

Thiard News@F4F

@newsen.bsky.social

9 months ago

Revolutionizing Cancer Diagnostics: Leica Biosystems' Cutting-Edge Digital Pathology Solutions Leica Biosystems is showcasing transformative digital pathology solutions at ECDP 2025, aiming to revolutionize cancer diagnostics and research.

Revolutionizing Cancer Diagnostics: Leica Biosystems' Cutting-Edge Digital Pathology Solutions #USA #Cancer_Diagnostics #Vista #Digital_Pathology #Leica_Biosystems

Thiard News@F4F

@newsen.bsky.social

10 months ago

Syantra Inc. Advances Cancer Screening and Treatment with New IP Filings Syantra Inc. has completed new patent filings that broaden its innovative work in cancer diagnostics and treatment, enhancing early cancer detection.

Syantra Inc. Advances Cancer Screening and Treatment with New IP Filings #Canada #Calgary #Cancer_Diagnostics #Onco-ID #Syantra_Inc.

Thiard News@F4F

@newsen.bsky.social

10 months ago

OncoSwab and Mayo Clinic Team Up for Innovative Cancer Tests OncoSwab partners with Mayo Clinic to enhance non-invasive cancer diagnosis using nasal swabs for early detection and biomarker analysis.

OncoSwab and Mayo Clinic Team Up for Innovative Cancer Tests #USA #San_Francisco #Cancer_Diagnostics #Mayo_Clinic #OncoSwab

Thiard News@F4F

@newsen.bsky.social

11 months ago

VolitionRX Limited: Transforming Disease Detection and Monitoring Through Innovative Technology in Global Markets VolitionRX Limited is making significant breakthroughs in diagnostics for life-altering diseases, offering groundbreaking solutions for humans and animals worldwide. Learn more about their impact.

VolitionRX Limited: Transforming Disease Detection and Monitoring Through Innovative Technology in Global Markets #United_States #Cancer_Diagnostics #Henderson #VolitionRx #Nu.Q_technology

Thiard News@F4F

@newsen.bsky.social

11 months ago

Cha-Mei Tang Recognized for Excellence in Pioneering Cancer Diagnostics Dr. Cha-Mei Tang has been acknowledged as a Pinnacle Professional Member for her groundbreaking work in cancer diagnostics and screening technology.

Cha-Mei Tang Recognized for Excellence in Pioneering Cancer Diagnostics #United_States #Cancer_Diagnostics #Potomac #Creatv_Bio #Cha-Mei_Tang

Thiard News@F4F

@newsen.bsky.social

1 year ago

VolitionRx to Present Innovative Insights on Nu.Q® Cancer Diagnostics in Upcoming Virtual Event On April 9, 2025, VolitionRx will host a virtual event showcasing their Nu.Q® cancer detection platform. Key executives will present groundbreaking findings and discuss future opportunities in cancer diagnostics.

VolitionRx to Present Innovative Insights on Nu.Q® Cancer Diagnostics in Upcoming Virtual Event #United_States #Cancer_Diagnostics #Henderson #VolitionRx #Nu.Q

Thiard News@F4F

@newsen.bsky.social

1 year ago

Volition's Nu.Q® Cancer Test Set to Transform the Liquid Biopsy Market with Accurate Detection VolitionRx's new automated Nu.Q® Cancer test shows promise in accurately detecting multiple cancers, potentially reshaping cancer diagnostics.

Volition's Nu.Q® Cancer Test Set to Transform the Liquid Biopsy Market with Accurate Detection #United_States #Cancer_Diagnostics #Henderson #Nu.Q #Volition

Thiard News@F4F

@newsen.bsky.social

1 year ago

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as Strategic Advisor for Innovative Cancer Solutions Datar Cancer Genetics has appointed Dr. Massimo Cristofanilli as a strategic advisor, enhancing its commitment to advancing cancer diagnostics and precision medicine.

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as Strategic Advisor for Innovative Cancer Solutions #USA #New_York #Cancer_Diagnostics #Datar_Cancer_Genetics #Massimo_Cristofanilli

Thiard News@F4F

@newsen.bsky.social

1 year ago

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as New Strategic Advisor Datar Cancer Genetics announces Dr. Massimo Cristofanilli as a strategic advisor, enhancing efforts in early cancer detection and personalized treatment strategies.

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as New Strategic Advisor #USA #New_York #Cancer_Diagnostics #Datar_Cancer_Genetics #Massimo_Cristofanilli

Thiard News@F4F

@newsen.bsky.social

1 year ago

Datar Cancer Genetics Welcomes Dr. Massimo Cristofanilli as Strategic Advisor for Cancer Diagnostics Dr. Massimo Cristofanilli joins Datar Cancer Genetics as a Strategic Advisor, aiming to enhance cancer detection and personalized treatment pathways. His expertise promises innovative solutions.

Datar Cancer Genetics Welcomes Dr. Massimo Cristofanilli as Strategic Advisor for Cancer Diagnostics #USA #New_York #Cancer_Diagnostics #Datar_Cancer_Genetics #Massimo_Cristofanilli

Thiard News@F4F

@newsen.bsky.social

1 year ago

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as Strategic Advisor Datar Cancer Genetics welcomes Dr. Massimo Cristofanilli as a Strategic Advisor, enhancing its efforts in cancer diagnostics and treatment.

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics as Strategic Advisor #United_States #New_York #Cancer_Diagnostics #Datar_Cancer_Genetics #Massimo_Cristofanilli

Thiard News@F4F

@newsen.bsky.social

1 year ago

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics to Propel Cancer Diagnostics Forward Dr. Massimo Cristofanilli has been appointed as Strategic Advisor at Datar Cancer Genetics, significantly boosting their cancer diagnostics efforts.

Dr. Massimo Cristofanilli Joins Datar Cancer Genetics to Propel Cancer Diagnostics Forward #USA #New_York #Cancer_Diagnostics #Datar_Cancer_Genetics #Massimo_Cristofanilli

Thiard News@F4F

@newsen.bsky.social

1 year ago

DELFI Diagnostics Appoints Dr. Amoolya Singh as New CTO to Advance Cancer Diagnostics DELFI Diagnostics elevates Dr. Amoolya Singh as Chief Technology Officer to lead innovations in blood-based cancer detection technology, enhancing early diagnosis capabilities.

DELFI Diagnostics Appoints Dr. Amoolya Singh as New CTO to Advance Cancer Diagnostics #United_States #Baltimore #Cancer_Diagnostics #DELFI_Diagnostics #Amoolya_Singh

Thiard News@F4F

@newsen.bsky.social

1 year ago

Revolutionary AI in Breast Cancer Screening Achieves Remarkable Success in Clinical Setting Lunit's AI-driven insight has transformed breast cancer screening, showcasing improved accuracy and efficiency in real-world applications since its deployment.

Revolutionary AI in Breast Cancer Screening Achieves Remarkable Success in Clinical Setting #South_Korea #Seoul #Breast_Cancer #Lunit_AI #Cancer_Diagnostics